Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

Asia Pac ECM and Index Rebal

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Quantitative Analysis

<ul>
<li>We analyze statistics on top repurchases over one week, one month, one quarter and one year periods ended on Oct 24th based on HKEx daily reports.</li>
<li>In the past 7 days, the top 3 companies that repurchased the most shares from the market were Xiaomi (1810 HK), China Mengniu Dairy (2319 HK), Linklogis (9959 HK).</li>
<li>In the past 30 days, the top 3 companies that repurchased the most shares from the market were Tencent (700 HK), Xiaomi (1810 HK), Anta (2020 HK).</li>
</ul>


We analyze statistics on top repurchases over one week, one month, one quarter and one year periods ended on Oct 24th based on HKEx daily reports.
In the past 7 days, the top 3 companies that repurchased the most shares from the market were Xiaomi (1810 HK), China Mengniu Dairy (2319 HK), Linklogis (9959 HK).
In the past 30 days, the top 3 companies that repurchased the most shares from the market were Tencent (700 HK), Xiaomi (1810 HK), Anta (2020 HK).


Hong Kong Buybacks Weekly (Oct 24th): Xiaomi, China Mengniu Dairy, Linklogis

<ul>
<li>We analyze statistics on top repurchases over one week, one month, one quarter and one year periods ended on Oct 17th based on HKEx daily reports.</li>
<li>In the past 7 days, the top 3 companies that repurchased the most shares from the market were Xiaomi (1810 HK), Tencent (700 HK), Shoucheng (697 HK).</li>
<li>In the past 30 days, the top 3 companies that repurchased the most shares from the market were Tencent (700 HK), Anta (2020 HK), Xiaomi (1810 HK).</li>
</ul>


We analyze statistics on top repurchases over one week, one month, one quarter and one year periods ended on Oct 17th based on HKEx daily reports.
In the past 7 days, the top 3 companies that repurchased the most shares from the market were Xiaomi (1810 HK), Tencent (700 HK), Shoucheng (697 HK).
In the past 30 days, the top 3 companies that repurchased the most shares from the market were Tencent (700 HK), Anta (2020 HK), Xiaomi (1810 HK).


Hong Kong Buybacks Weekly (Oct 17th): Xiaomi, Tencent, Shoucheng

Pan-Asia Catalysts/Events, Quiddity Advisors

David Blennerhassett

Pan-Asia Catalysts/Events

Quiddity Advisors

Event-Driven

<ul>
<li>As with large, clean liquid deals in Asia-Pac, expect <a href="https://www.smartkarma.com/entities/hang-seng-bank-ltd" target="_blank" data-smartkarma-citation="entities:24:1" rel="noopener">Hang Seng (11 HK)</a>'s annualised spreads to widen (i.e. gross spread remains static) as investors hit their full quota early on. </li>
<li>The question is whether <a href="https://www.smartkarma.com/entities/soft99-corp" target="_blank" data-smartkarma-citation="entities:18486:1" rel="noopener">Soft99 (4464 JP)</a>'s MBO Bidco raises the price to  ¥3,200 saying "let's split the difference", and that would make some people happy. It's doubtful they will.</li>
<li>
<a href="https://www.smartkarma.com/entities/sihuan-pharmaceutical-hldgs" target="_blank" data-smartkarma-citation="entities:33:1" rel="noopener">Sihuan Pharmaceutical (460 HK)</a> has benefited a little from the HK$500mn buyback programme announced last October. But a HK$11bn run up in market cap YTD? This looks stretched to me.</li>
</ul>


As with large, clean liquid deals in Asia-Pac, expect Hang Seng (11 HK)'s annualised spreads to widen (i.e. gross spread remains static) as investors hit their full quota early on. 
The question is whether Soft99 (4464 JP)'s MBO Bidco raises the price to  ¥3,200 saying "let's split the difference", and that would make some people happy. It's doubtful they will.

Sihuan Pharmaceutical (460 HK) has benefited a little from the HK$500mn buyback programme announced last October. But a HK$11bn run up in market cap YTD? This looks stretched to me.


Last Week In Event SPACE: Hang Seng Bank, Soft99, Sihuan Pharma, Dongfeng Motor

Global Healthcare Analyst

Tina Banerjee

Equity Capital Markets

Xuanzhu Biopharmaceutical / Equity Capital Markets

<ul>
<li>Xuanzhu Biopharmaceutical has filed for IPO to raise up to HK$781M. The company plans to sell 67.3M shares at HK$11.6 per share.</li>
<li>Xuanzhu Biopharmaceutical is an innovation-driven biopharmaceutical company focused on developing treatment options in the fields of digestive diseases, oncology and non-alcoholic steatohepatitis (NASH).</li>
<li>2026 will be an inflection point for the company with all three core products fully commercialized, but will not be enough for the company to establish a sustainable market play.</li>
</ul>


Xuanzhu Biopharmaceutical has filed for IPO to raise up to HK$781M. The company plans to sell 67.3M shares at HK$11.6 per share.
Xuanzhu Biopharmaceutical is an innovation-driven biopharmaceutical company focused on developing treatment options in the fields of digestive diseases, oncology and non-alcoholic steatohepatitis (NASH).
2026 will be an inflection point for the company with all three core products fully commercialized, but will not be enough for the company to establish a sustainable market play.


Xuanzhu Biopharma IPO: Lacks Product Differentiation, Investors Can Give It a Pass For Now

<ul>
<li>On the 12th November 2024, <a href="https://www.smartkarma.com/entities/sihuan-pharmaceutical-hldgs" target="_blank" data-smartkarma-citation="entities:33:1" rel="noopener">Sihuan Pharmaceutical (460 HK)</a> proposed spinning-off the shares of Xuanzhu Biopharm on the main board of Hong Kong.</li>
<li>
<a href="https://www.smartkarma.com/entities/xuanzhu-biopharmaceutical-co-ltd" target="_blank" data-smartkarma-citation="entities:44117:1" rel="noopener">Xuanzhu Biopharmaceutical</a>'s prospectus is now out. Shares are priced at HK$11.60/share, backing out a market cap of ~HK$6bn vs. Sihuan Pharma's HK$17.4bn market cap. Trading commences on the 15th October.</li>
<li>Sihuan Pharma will hold 49.1% post IPO. Its share price is up 189% YTD. Looks frothy. Then again, so does Hong Kong's IPO market.</li>
</ul>


On the 12th November 2024, Sihuan Pharmaceutical (460 HK) proposed spinning-off the shares of Xuanzhu Biopharm on the main board of Hong Kong.

Xuanzhu Biopharmaceutical's prospectus is now out. Shares are priced at HK$11.60/share, backing out a market cap of ~HK$6bn vs. Sihuan Pharma's HK$17.4bn market cap. Trading commences on the 15th October.
Sihuan Pharma will hold 49.1% post IPO. Its share price is up 189% YTD. Looks frothy. Then again, so does Hong Kong's IPO market.


Sihuan Pharma (460 HK): On Xuanzhu Biopharm's Imminent Spin-Off

China

Sihuan Pharmaceutical is a pharmaceutical and medical aesthetic company engaged in the research, development, manufacturing, and sale of products. It offers drugs across therapeutic areas such as oncology, metabolism, diabetes, and cardiovascular diseases, alongside medical aesthetic solutions. The company was founded in 2001 and is headquartered in Wan Chai, Hong Kong.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Sihuan Pharmaceutical (460 HK)

Hong Kong Buybacks Weekly (Oct 24th): Xiaomi, China Mengniu Dairy, Linklogis

We analyzed the Hong Kong buyback data in the past week and highlight the top 3 companies that repurchased the most shares were Xiaomi (1810 HK),...

Ke Yan, CFA, FRM

Hong Kong Buybacks Weekly (Oct 17th): Xiaomi, Tencent, Shoucheng

We analyzed the Hong Kong buyback data in the past week and highlight the top 3 companies that repurchased the most shares were Xiaomi (1810 HK),...

Ke Yan, CFA, FRM

Last Week In Event SPACE: Hang Seng Bank, Soft99, Sihuan Pharma, Dongfeng Motor

It’s Sunday! Pour yourself a coffee, grab a comfortable seat, and sift through a brief summary of insights on various events discussed during the...

David Blennerhassett

Xuanzhu Biopharma IPO: Lacks Product Differentiation, Investors Can Give It a Pass For Now

Xuanzhu Biopharmaceutical files for IPO to raise HK$781M. 2026 is a crucial year for the company's commercialization efforts. Lacks product...

Tina Banerjee

Sihuan Pharma (460 HK): On Xuanzhu Biopharm's Imminent Spin-Off

Sihaun Pharma has benefited a little from the HK$500mn, 12-month buyback programme announced on the 6th October 2024. But a HK$11bn run up in...

David Blennerhassett

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Hong Kong Buybacks Weekly (Oct 24th): Xiaomi, China Mengniu Dairy, Linklogis

We analyzed the Hong Kong buyback data in the past week and highlight the top 3 companies that repurchased the most shares were Xiaomi (1810 HK),...

Ke Yan, CFA, FRM

Hong Kong Buybacks Weekly (Oct 17th): Xiaomi, Tencent, Shoucheng

We analyzed the Hong Kong buyback data in the past week and highlight the top 3 companies that repurchased the most shares were Xiaomi (1810 HK),...

Ke Yan, CFA, FRM

Last Week In Event SPACE: Hang Seng Bank, Soft99, Sihuan Pharma, Dongfeng Motor

It’s Sunday! Pour yourself a coffee, grab a comfortable seat, and sift through a brief summary of insights on various events discussed during the...

David Blennerhassett

Xuanzhu Biopharma IPO: Lacks Product Differentiation, Investors Can Give It a Pass For Now

​Xuanzhu Biopharmaceutical files for IPO to raise HK$781M. 2026 is a crucial year for the company's commercialization efforts. Lacks product...

Tina Banerjee

Sihuan Pharma (460 HK): On Xuanzhu Biopharm's Imminent Spin-Off

Sihaun Pharma has benefited a little from the HK$500mn, 12-month buyback programme announced on the 6th October 2024. But a HK$11bn run up in...

David Blennerhassett

Xuanzhu Biopharmaceutical files for IPO to raise HK$781M. 2026 is a crucial year for the company's commercialization efforts. Lacks product...